XML 43 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
STOCKHOLDERS' EQUITY
 9 Months Ended
Mar. 31, 2015
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY

NOTE 6: - STOCKHOLDERS' EQUITY

  a. From July 2014 through March 2015, a total of 1,531,367 warrants were exercised via “cashless” exercise, resulting in the issuance of 694,326 shares of common stock to investors of the Company.  In addition, 147,667 warrants were exercised for cash and resulted in the issuance of 147,667 shares of common stock to investors of the Company. The aggregate cash consideration received was $244.
 
  b. In October 2014, the Company issued 200,000 shares of common stock to an investor, in a private placement. The aggregate cash consideration received was $528. In February 2015, the Company issued an additional 200,000 shares of common stock to an investor, in a private placement. The aggregate cash consideration received was $586.
 
  c. In December 2014, the Company granted 100,004 shares of restricted stock to its new laboratories facility contractor. The shares of restricted stock are linked to performance milestones with respect to the building of new laboratories in the Company's leased facility. As of March 31, 2015, these milestones have not been met. The fair value of the restricted stock as of March 31, 2015, amounted to approximately $280.
 
  d. Options, warrants and restricted stock units to employees, directors and consultants:

  1.

Options to employees and directors:


A summary of the Company's activity related to options granted to employees and directors under the Company's 2003 and 2005 option plans is as follows:



 Nine months ended March 31, 2015 (Unaudited)            
     Number      Weighted Average
Exercise Price		      Weighted Average
Remaining
Contractual Terms
(in years)		      Aggregate Intrinsic
Value Price
Options outstanding at beginning of period     1,862,099     $ 3.73                
Options exercised     (8,000 )   $ 0.88                
Options forfeited     (423 )    $ 4.40                
Options outstanding at end of the period     1,853,676     $ 3.74       2.37     $ 895
Options exercisable at the end of the period     1,853,676     $ 3.74       2.37     $ 895
Options vested     1,853,676     $ 3.74       2.37     $ 895
   
Intrinsic value of exercisable options (the difference between the Company's closing stock price on the last trading day in the period and the exercise price, multiplied by the number of in-the-money options) represents the amount that would have been received by the employees and directors option holders had all option holders exercised their options on March 31, 2015. This amount changes based on the fair market value of the Company's common stock.
 
  2.

Options and warrants to non-employees:
  A summary of the activity related to options and warrants to consultants is as follows:
           
   Nine months ended March 31, 2015 (Unaudited)           

   Number      Weighted 
Average
Exercise Price		      Weighted
Average
Remaining
Contractual
Terms (in years)		      Aggregate
 Intrinsic Value 
Price
Options and warrants outstanding at beginning of period     252,000     $ 5.19                
Options granted     1,000     $ 0.00001                  
Options and warrants outstanding at end of the period     253,000     $ 5.17       3.23     $ 297
                               
Options and warrants exercisable at the end of the period     252,000     $ 5.19       3.21     $ 294
                               
Options and warrants vested and expected to vest     253,000     $ 5.17       3.23     $ 297
 
Compensation expenses related to options and warrants granted to consultants were recorded as follows:
 
Nine months ended March 31, Three months ended March  31,
2015 2014 2015   2014
Research and development expenses   $ 1     $ 7   $          -     $             7
General and administrative expenses   $  1       -   $  1       -
    $ 2     $ 7   $          1     $             7

  3.

Restricted stock units to employees and directors:


During the nine month period ended March 31, 2015, the Company granted restricted stock units to several of the Company's employees and directors.


The following table summarizes the activity related to unvested restricted stock units granted to employees and directors for the nine-month period ended March 31, 2015 (Unaudited):

 

  Number  
Unvested at the beginning of period 1,589,432  
Granted 1,028,153  
Forfeited (22,676 )
Vested (1,021,757 )
Unvested at the end of the period 1,573,152  
Expected to vest after March 31, 2015 1,510,189  

 

Compensation expenses related to restricted stock units granted to employees and directors were recorded as follows:

 

Nine months ended March 31, Three months ended March 31,
     2015      2014      2015      2014
Research and development expenses   $ 977     $ 656     $ 482     $ 442
General and administrative expenses     1,735       3,299       592       1,196
    $ 2,712     $ 3,955     $ 1,074     $ 1,638

     

Unamortized compensation expenses related to restricted stock units granted to employees and directors to be recognized over an average time of approximately 2 years is $2,388.

 

  4.

Restricted stock units to consultants:


During the nine month period ended March 31, 2015, the Company granted restricted stock units to several consultants and service providers.


The following table summarizes the activity related to unvested restricted stock units granted to consultants for the nine months ended March 31, 2015:           

  Number  
Unvested at the beginning of period 15,250  
Granted 70,180  
Forfeited -  
Vested (69,805 )
Unvested at the end of the period 15,625  
Expected to vest after March 31, 2015 15,625  

       Compensation expenses related to restricted stock units granted to consultants were recorded as follows:

Nine months ended March 31, Three months ended  March 31,
2015 2014 2015   2014
Research and development expenses   $ 110     $ 59     $ 33     $ 42
General and administrative expenses     88       157       50     157
    $ 198     $ 216     $ 83     $ 199